Attached files
| file | filename |
|---|---|
| 10-K - 10-K - CALADRIUS BIOSCIENCES, INC. | clbs-10kx20171231.htm |
| EX-10.1 - EXHIBIT 10.1 - CALADRIUS BIOSCIENCES, INC. | exhibit101directorcompensa.htm |
| EX-23.1 - EXHIBIT 23.1 - CALADRIUS BIOSCIENCES, INC. | exh2312018.htm |
| EX-31.1 - EXHIBIT 31.1 - CALADRIUS BIOSCIENCES, INC. | clbs-ex311_20181231xq4.htm |
| EX-31.2 - EXHIBIT 31.2 - CALADRIUS BIOSCIENCES, INC. | clbs-ex312_20181231xq4.htm |
| EX-14.1 - EXHIBIT 14.1 - CALADRIUS BIOSCIENCES, INC. | exhibit141.htm |
| EX-32 - EXHIBIT 32 - CALADRIUS BIOSCIENCES, INC. | clbs-ex32_20181231.htm |
Exhibit 21.1
Subsidiaries of Caladrius Biosciences, Inc.
Entity | Percentage of Ownership | Location | ||
Amorcyte, LLC | 100% | United States of America | ||
Athelos Corporation (1) | 97% | United States of America | ||
NeoStem Oncology, LLC | 100% | United States of America | ||
(1) As of December 31, 2017, Becton Dickinson's ownership interest in Athelos Corporation was 1.6%.